12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

EC145 regulatory update

Endocyte announced a new timeline for seeking conditional approval in the EU of cancer compound EC145 and diagnostic imaging agent EC20. Endocyte also said the European Commission granted Orphan Drug designation for the products. In 3Q12, the company plans to...

Read the full 187 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >